When Howard Chang, 50, first learned about biologic treatments for psoriasis almost 20 years ago, he was eager to give them a try. Now they’re a mainstay in his overall treatment plan.

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

Early biologic response patterns in plaque psoriasis revealed faster remission with anti-IL-17AF and underscored the need for tailored treatment strategies.

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

Biologics are the heavy hitters for treating people with moderate-to-severe psoriasis who haven’t had good results with other medications. They target the specific parts of an overactive immune ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

SAN DIEGO — Disease-modifying antirheumatic drugs (DMARDs) and biologics were linked to as much as a 74.5% reduction in the risk for alopecia areata (AA) in patients with psoriasis, a new ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...

Researchers have found in a recent analysis reveals IL-17 inhibitors significantly increase the risk of Candida infections ...